Personal profile
Research interests
My primary research interest is the origins of childhood lung disease, particularly the pathophysiology of CF lung disease in infancy and early childhood.
Clinical interests
Early childhood lung disease, cystic fibrosis, primary ciliary dyskinesia, asthma, pulmonary function testing, infant pulmonary function testing, multiple breath washout testing.
Fingerprint
Dive into the research topics where Jessica Pittman is active. These topic labels come from the works of this person and are generated automatically. Together they form a unique fingerprint. Contact the Profiles team with questions.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis
Sagel, S. D., Vu, P., Heltshe, S. L., Solomon, G. M., Kelly, A., Pittman, J., Rosenfeld, M. & Ratjen, F., May 2026, In: Journal of Cystic Fibrosis. 25, 3, p. 450-456 7 p.Research output: Contribution to journal › Article › peer-review
4 Link opens in a new tab Scopus citations -
Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy
Green, N., Vu, P., Xie, J., Schwarzenberg, S. J., Freedman, S., Narkewicz, M., Pittman, J., Ratjen, F., Rosenfeld, M., Pope, C., Duong, J., Hoffman, L., Heltshe, S. & Lusman, S. S., 2026, (Accepted/In press) In: Journal of Cystic Fibrosis.Research output: Contribution to journal › Article › peer-review
Open Access -
Airway Disease Progression on Chest Computed Tomography in Children With Primary Ciliary Dyskinesia
for the Genetic Disorders of Mucociliary Clearance Consortium, Sep 2025, In: Pediatric Pulmonology. 60, 9, e71287.Research output: Contribution to journal › Article › peer-review
Open Access4 Link opens in a new tab Scopus citations -
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6-to 11-Year-Olds with Cystic Fibrosis An Observational Study
the PROMISE Pediatric substudy Investigators, Nov 1 2025, In: Annals of the American Thoracic Society. 22, 11, p. 1696-1708 13 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Link opens in a new tab Scopus citations -
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
VX21-121-105 Study Group, Mar 2025, In: The Lancet Respiratory Medicine. 13, 3, p. 244-255 12 p.Research output: Contribution to journal › Article › peer-review
Open Access44 Link opens in a new tab Scopus citations